Abstract
Get full access to this article
View all access options for this article.
References
1.
Wallach
JD
Ross
JS
Naci
H
. FDA’s expedited approval programs: evidentiary standards, regulatory trade-offs, and potential improvements . Clin Trials 2018 ; 3 : 243 –246 .
2.US Food and Drug Administration (FDA) . Guidance for industry: expedited programs for serious conditions—drugs and biologics , https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf (2014 , accessed 15 January 2018 ).
3.
Pinnow
E
Amr
S
Bentzen
SM
et al
. Postmarket safety outcomes for new molecular entity (NME) drugs approved by the Food and Drug Administration between 2002 and 2014 . Clin Pharmacol Ther . Epub ahead of print 20 December 2017 . DOI: 101002/cpt.944.
4.US Food and Drug Administration (FDA) . Guidance for industry: providing clinical evidence of effectiveness for human drugs and biological products , https://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4227B1-02-02-FDA-Appendix1.pdf (1998 , accessed 20 January 2018 ).
5.Friends of Cancer Research . Breakthrough therapies , https://www.FOCR.org/breakthrough-therapies?title=&field_sponsor_value=&field_fda_status_value%5B%5D=2 (accessed 20 January 2018 ).